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manufacturers. There are several options for remedy such as a more comprehensive 
product review programme, but this could lead to further delays.
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Objectives: Since the health care reform in Germany (AMNOG) in 2011, newly 
approved drugs have to demonstrate their innovation to avoid reference group 
pricing. The pharmaceutical manufacturer (PM) has to submit a dossier proving 
additional benefit versus the appropriate comparator recommended by the G-BA 
(Joint Federal Committee). MethOds: Benefit assessments and G-BA decisions 
to date were analyzed. Outcome data, indirect comparisons and decisions (until 
January 2015) were explored with regard to factors potentially impacting the out-
come of price negotiations. Results: 148 agents entered the assessment process, 
102 dossier completed the whole assessment process. G-BA evaluations resulted 
in 26 minor, 21 considerable, and 55 not quantifiable/no additional therapeutic 
benefit of assessed vs. comparator drug. In 29 cases the G-BA did not follow IQWiG’s 
conclusions of the extent of additional benefit. The choice of appropriate com-
parator was controversial between G-BA and PM in 10 cases, followed by questions 
about evidence of benefit. 5 drugs, which failed to prove an additional benefit, were 
withdrawn from the German market. In a sub-analysis 18 drugs were examined, 
where the reimbursed price has been negotiated between the National Association 
of Statutory Health Insurance Funds (GKV-SV) and PM. The mean rebate was 17% 
with a range from 0 to 52%. Negotiated rebates were not correlated with any of the 
clinical and economic parameters (e.g. number of patients benefitting, proposed 
price) analyzed. cOnclusiOns: AMNOG mediates price control despite mandatory 
reimbursement of innovative drugs. Following initial pitfalls in dossier develop-
ment the withdrawal of 5 drugs in 2012 may indicate that nowadays either the PMs 
are more familiar with AMNOG or, that drugs with limited potential of proving an 
additional benefit tend to be not launched in Germany. The majority of price nego-
tiations resulted in reductions of < 20%. It was not possible to identify parameters 
predicting the magnitude of rebates.
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Objectives: Early market access schemes are expanding across the globe, pre-
senting health technology suppliers with a variety of opportunities for expediting 
product approval. This paper aims to provide an overview of three such schemes: 
the ‘conditional approval’ opportunity in Japan’s Pharmaceuticals, Medical Devices 
and Other Therapeutic Products (PMD) Act; the UK’s Early Access to Medicines 
Scheme (EAMS); and the Breakthrough Therapy (BT) designation program in 
the US. MethOds: Secondary research identified market-specific early access 
schemes and key themes were evaluated. Where available, quantitative data were 
analyzed. Hypotheses were generated and then validated during in-depth inter-
views with key stakeholders across markets. Results: The US BT designation 
is the most advanced early access opportunity, having been established in July 
2012. Of the 212 technologies reviewed so far, 35% have gained BT status. Through 
December 2014, 16 have subsequently obtained full approval. Launched in the 
UK in April 2014, the EAMS has had three promising innovative medicine (PIM) 
designations, which forms the first of two steps in gaining early market access. In 
Japan, the conditional approval scheme focuses on regenerative medicines and, 
while interest is significant, the program is in its infancy, having been formalized 
in November 2014. cOnclusiOns: Health technology suppliers need to evaluate 
associated costs and benefits when determining whether any of the early access 
routes are appropriate for a novel product. One consideration is the type of tech-
nology in scope: developers of regenerative cell therapies should consider the 
Japanese scheme, but will need to leverage local partnerships in order to facilitate 
access. Another consideration is the costs involved in application, and whether the 
technology is reimbursed during the program. While products are reimbursed in 
Japan, UK reimbursement is not guaranteed. The BT program is the most mature 
and globally recognized of the three, and offers ongoing regulatory support until 
final marketing authorization.
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Objectives: HTA agencies in both Germany (IQWiG) and France (TC) focus on 
additional benefits without explicit consideration of cost in their HTA assessment. 
While the German Federal Joint Committee (GBA) usually commissions IQWiG for 
the assessment, the GBA makes final decisions on the level of additional benefit 
provided by a new therapy. We sought to document whether the GBA and TC 
reached the same rankings for the same drug indication evaluated. MethOds: 
We first searched GBA assessments conducted from August 2011 to July 2014 and 
then cross checked whether the TC completed its own assessment for the same 
indication. The GBA classifies additional benefits as “Major, Considerable, Minor, 
Non-quantifiable, No Benefit, and Less Benefit”. For the TC, they are categorized as 
“Major, Important, Significant, Minor, No Improvement, Do Not Recommend”. We 
also examined the comparators used in the assessments. Results: A total of 67 
indications were evaluated by both agencies. No indication was awarded “Major” 
by either agency. For 17 “Considerable” ranking granted by the GBA, 2 were given 
“Important”, 8 “Significant”, 6 “Minor”, and 1 “No Improvement” by the TC. For 21 
“Minor” ranking awarded by the GBA, 1 was considered “Significant”, 11 “Minor”, 
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Objectives: Under the positive drug listing system, pharmaceutical companies in 
Korea are required to provide cost-effectiveness (CE) evidence of newly approved 
drugs for listing on the National Health Insurance (NHI) drug formulary. It has been 
argued that selection criteria of comparator treatments suggested by the CE guide-
line are too limited and unrealistic to conduct a valid CE assessment. Therefore, 
our study was conducted to investigate types of practical problems in comparator 
selection in order to improve the validity of CE analysis. MethOds: We conducted 
focus group interviews (FGI) with experts working in research-based drug compa-
nies, charged of submitting CE evidence of their products to NHI. Each participant 
received an interview question via an e-mail beforehand and presented their opin-
ions at round-table discussion. Results: Examples of the problems associated with 
selecting appropriate comparators identified from FGI are as follows: drugs with 
the same indication, but therapeutically nonequivalent, were used as comparators ; 
there is no guidance on whether to include off-label drugs as comparators; when off-
patent products were selected as comparators, the price of the new drug was com-
pared with the price of generic products rather than the initial price of the original 
products set during the patent period; it is difficult to obtain reliable market share 
data needed for selecting a comparator; and the best supportive care was selected as 
a comparator when there’s no appropriate treatment alternatives. cOnclusiOns: 
We expect that the results of our investigation would contribute to improve the 
quality of CE guidelines in South Korea as well as other countries, and to improve 
assessment of the true value of pharmaceutical intervention.
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Objectives: To establish a working definition of “quality” in the HTA context; to 
identify the key features of good-quality HTA submission and review performance. 
The outcome of the research will be used to facilitate the development and adoption 
of best practices in HTA submissions, assessment processes and decision mak-
ing. MethOds: The research was initiated by identifying common elements that 
underpin a quality submission dossier, and a set of key performance indicators 
(KPIs) of HTA review processes and procedures. International experts representing 
HTA/coverage agencies, academics and pharmaceutical companies were invited 
to discuss the identified parameters from diverse viewpoints. The key discussion 
points and recommendations for KPIs are outlined herein. Results: Four elements 
of a quality dossier were identified: robustness and relevance of the scientific data; 
dossier completeness, that is, the inclusion of all relevant information; integrity or 
consistency; and logical structure and clear format. Quality of HTA review is most 
easily measured by assessing outcomes of tools designed to ensure or to support 
good-quality process such as internal and external peer reviews, audits, standard 
operating procedures and procedures for learning and feedback. Ten KPIs of the HTA 
review process considered important from a company’s perspective were identified 
as well the four main areas from HTA agencies perspective: timeliness, relevance, 
credibility and impact. cOnclusiOns: A key outcome of this research was a clear 
understanding of “quality” in the context of HTA across stakeholders, and the iden-
tification of key factors, irrespective of the diversity of HTA agencies, which could 
be used to measure the quality of process. The next phase of the research will be to 
develop an instrument to measure quality of HTA process based on identified KPIs 
and to be piloted and validated by key stakeholders.
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Objectives: In contrast to the Scottish Medicines Consortium, NICE does not 
evaluate all new medicines, but uses a set of specific selection criteria. Where a 
technology is not selected for assessment the affected products may face difficul-
ties in achieving payer and physician uptake. We aim to demonstrate and evaluate 
the difficulties faced by those seeking market access for products and the conse-
quence of non-selection. Whilst oncology products currently have the Cancer Drugs 
Fund (CDF) to fall back on, there is an issue of how NICE, CDF and NHS England 
policies will work together in the future. We further consider the possible options, 
both for delaying and non-assessment, or failure to obtain reimbursement through 
other routes. MethOds: We review the topic selection methodologies and com-
pare the number of marketing authorizations approved in recent years and those 
products reviewed by NICE. Examples of orphan drugs that have not been selected 
are provided. We further review opportunities for redress for the manufacturer 
where they are not subject to a technology appraisal. Results: The position of a 
company seeking reimbursement for a new product that has not been reviewed 
by NICE is precarious, forcing them to rely on NHS England policies, local com-
missioner approvals, individual hospitals within CCGs or, ultimately, legal redress. 
Currently, there are over 20 NHS England policies to support the commissioning 
of products, and services associated with those products; and over 100 awaiting 
review. The common characteristic accompanying success is strong clinical support 
from the relevant NHS England clinical reference group and powerful patient lob-
bying. cOnclusiOns: The current position, whether caused by delay or a positive 
decision by NICE not to review, is considered unsatisfactory both for patients and 
